J&J’s First-Quarter Profit Beats Estimates Even as Stelara Sales Disappoint

Why It Matters

The earnings beat demonstrates J&J’s ability to offset a major product’s decline with other portfolio winners, preserving earnings momentum and supporting a higher full‑year outlook, which is critical for investors and the broader pharma market navigating biosimilar disruption.

Key Takeaways

• Q1 revenue up 10% to $24.1 billion, beating estimates
• Adjusted EPS $2.70, surpassing $2.66 consensus
• Stelara sales plunge 60% to $656 million after patent loss
• Darzalex and Tremfya drive growth, offsetting Stelara decline
• J&J raises full‑year forecast; shares up 15% YTD

Pulse Analysis

Johnson & Johnson’s latest quarterly report underscores the resilience of a diversified drug pipeline in a market increasingly crowded with biosimilars. While the company posted $24.1 billion in revenue—a near‑10% rise from the prior year—its earnings per share of $2.70 also outperformed consensus estimates. This performance reflects not only robust demand for newer oncology and dermatology treatments but also disciplined cost management that helped preserve margins despite the loss of a blockbuster’s exclusivity.

Stelara, once a $10 billion‑a‑year revenue engine, fell sharply after its patent expired, with sales slashing 60% to $656 million. The entry of multiple biosimilar competitors eroded its market share, a challenge that many legacy biologics now face. However, J&J’s strategic focus on expanding the reach of Darzalex, a multiple‑myeloma therapy, and Tremfya, a psoriasis drug, provided a counterbalance. These products delivered double‑digit growth, illustrating how targeted investment in high‑potential assets can mitigate the impact of patent cliffs.

Looking ahead, the company’s decision to raise its full‑year outlook signals confidence in its ability to sustain growth through portfolio diversification and pipeline advancements. Investors have responded positively, with the stock up roughly 15% year‑to‑date, though short‑term volatility remains. The broader implication for the pharmaceutical sector is clear: firms that proactively manage patent expirations by nurturing next‑generation therapies are better positioned to maintain earnings momentum and shareholder value in an era of heightened competition.